SastiMedic
Icupen 500 mg Injection

Icupen 500 mg Injection

MRP: ₹2,850.00

Packaging

INJECTION

Composition

Doripenem 500mg

Company

Abbott India

Buy Now

Substitutes for Icupen 500 mg Injection

Medicine Company Price You Save
Mydor 500mg Injection Mylan Pharmaceuticals ₹1,999.00 Save ₹851.00
Nozodor 500mg Injection Samarth Pharma ₹2,900.00
Dorinosa 500mg Injection Natco Pharma ₹2,950.00
Doricrit 500 mg Injection Cipla ₹3,200.00
Doribax 500mg Injection J&J ₹3,220.00

Side Effects of Icupen 500 mg Injection

Headache, nausea, diarrhoea, rash, phlebitis, elevated hepatic enzymes, oral candidiasis, anaemia, vulvomycotic infection, renal impairment, neutropenia, leucopenia, thrombocytopenia. Potentially Fatal: Anaphylaxis, toxic epidermal necrolysis, Stevens-Johnson Syndrome, interstitial pneumonia, seizure.

Drug Interactions

May decrease valproic acid serum concentrations. Probenecid may increase serum levels of doripenem and concomitant use is not recommended.

Contraindications

Hypersensitivity; anaphylactic reactions to beta-lactams.

Mechanism of Action

Doripenem is a broad-spectrum carbapenem with potent in vitro antibacterial activity against aerobic and anaerobic gram-positive and gram-negative bacteria including Pseudomonas aeruginosa. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins; which in turn inhibits the final transpeptidase step of peptidoglycan synthesis in bacterial cell walls. Absorption: Cmax and AUC are linear over a dose range of 0.5-1 g when given over 1 hr by IV infusion. Distribution: Average binding to plasma proteins: About 8.1%; independent of plasma drug concentrations. Median Vd: 16.8 L Metabolism: Primarily metabolised by dehydropeptidase-I to a microbiologically inactive ring-opened metabolite. Excretion: Primarily excreted in urine (about 70% as unchanged drug, about 15% as ring-opened metabolite); faeces (≤1%). Mean half-life elimination in healthy adults: About 1 hr.

Special Precautions

May decrease serum concentration of valproic acid to below therapeutic range thus increasing risk of breakthrough seizure; consider alternative antimicrobial agents or additional anti-seizure medications if concurrent usage is necessary. Prolonged use may result in Clostridium difficile-associated diarrhoea (CDAD). May cause development of drug-resistant bacteria when used in the absence of proven or strongly suspected bacterial infection. Renal impairment. Safety and efficacy have not been established in patients <18 yr old.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

  • Alcohol: Avoid during treatment.
  • Breastfeeding: Not recommended.
  • Pregnancy: Contraindicated.
  • Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.

More brands by Abbott India

Written by: SastiMedic Medical Team

Reviewed by: Registered Pharmacist